北美的幻覺劑市場-產業趨勢和2029年為止的預測

北美的幻覺劑的市場規模在2022年～2029年的預測期間內預計將以13.4％的年複合成長率擴大。

本報告提供北美的幻覺劑市場相關調查，提供市場概要，以及各類型，來歷，藥物，各用途，各給藥途徑，各終端用戶，各流通管道，各國的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 市場區隔

第3章 摘要整理

第4章 重要考察

• 流行病學
• 開發平台分析

第5章 法律規範:北美的幻覺劑市場

• 美國的法規方案
• 英國的法規方案
• 印度的法規方案
• 阿拉伯聯合大公國的法規方案
• 非洲的法規方案
• 巴西的法規方案

第6章 市場概要

• 促進因素
• 阻礙因素
• 機會
• 課題

第7章 COVID-19影響

第8章 北美的幻覺劑市場，各類型

• 概要
• 病原體
• 離解性麻醉劑
• 其他

第9章 北美的幻覺劑市場，各來歷

• 概要
• 合成
• 天然

第10章 北美的幻覺劑市場，各藥物

• 概要
• γ-羥基丁酸
• 氯胺酮
• 賽洛西賓
• 其他

第11章 北美的幻覺劑市場，各用途

• 概要
• 猝睡症
• 抗治療性憂鬱症
• 重度憂鬱症
• 類鴉片物質依賴症
• 創傷後壓力症候群
• 其他

第12章 北美的幻覺劑市場，各給藥途徑

• 概要
• 口服
• 吸入
• 注射

第13章 北美的幻覺劑市場，各終端用戶

• 概要
• 醫院
• 專門診所
• 居家照護
• 其他

第14章 北美的幻覺劑市場，各流通管道

• 概要
• 院內藥局
• 零售藥局
• 線上藥局

第15章 北美的幻覺劑市場，各地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥

第16章 北美的幻覺劑市場:公司形勢

第17章 SWOT分析

第18章 企業簡介

• JAZZ PHARMACEUTICALS, INC.
• JANSSEN PHARMACEUTICALS, INC.
• PFIZER INC.
• AVADEL
• CELON PHARMA S.A.
• COMPASS
• CYBIN CORP.
• DEMERX
• EMPATHBIO
• F. HOFFMANN-LA ROCHE LTD
• GABA THERAPEUTICS, INC.
• HIKMA PHARMACEUTICALS PLC
• MIND MEDICINE INC.
• NEURORX, INC.
• PHARMATHER HOLDINGS LTD.
• USONAINSTITUTE.ORG
• VERRIAN

第19章 詢問調查

第20章 相關報告

North America psychedelic drugs market is projected to register a substantial CAGR of 13.4% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

North America Global Psychedelic Drugs Market, By Source (Synthetic & Natural), Type (Empathogens, Dissociatives & Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy)

Country (U.S., Canada, Mexico and Rest of North America) Industry Trends and Forecast to 2029.

Some of the major factors affecting the growth of North America psychedelic drugs market are:

Due to increasing prevalence of depression and mental disorder

Growing Acceptance Of Psychedelic Drugs For Treating Depression

Market Players:

The key market players for North America psychedelic drugs market are listed below:

Jazz Pharmaceuticals, Inc.

Janssen Global Services, LLC (a subsidiary of Johnson & Johnson Services, Inc.)

Hikma Pharmaceuticals PLC

COMPASS

Pfizer Inc.

Avadel

Cybin Corp.

Entheon Biomedical Corp

PharmaTher Holdings Ltd.

NRx Pharmaceuticals, Inc.

usonainstitute.org

TABLE OF CONTENTS

1 INTRODUCTION 24

• 1.1 OBJECTIVES OF THE STUDY 24
• 1.2 MARKET DEFINITION 24
• 1.3 OVERVIEW OF NORTH AMERICA PSYCHEDELIC DRUGS MARKET 24
• 1.4 LIMITATIONS 26
• 1.5 MARKETS COVERED 26

2 MARKET SEGMENTATION 29

• 2.1 MARKETS COVERED 29
• 2.2 GEOGRAPHICAL SCOPE 30
• 2.3 YEARS CONSIDERED FOR THE STUDY 31
• 2.4 CURRENCY AND PRICING 31
• 2.5 DBMR TRIPOD DATA VALIDATION MODEL 32
• 2.6 MULTIVARIATE MODELLING 35
• 2.7 TYPE LIFELINE CURVE 35
• 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
• 2.9 DBMR MARKET POSITION GRID 37
• 2.10 MARKET END USER COVERAGE GRID 38
• 2.11 VENDOR SHARE ANALYSIS 39
• 2.12 SECONDARY SOURCES 40
• 2.13 ASSUMPTIONS 40

3 EXECUTIVE SUMMARY 41

4 PREMIUM INSIGHT 45

• 4.1 PIPELINE ANALYSIS 46
• 4.2 PESTEL ANALYSIS 48
• 4.3 PORTER'S FIVE FORCES MODEL 49

5 REGULATORY FRAMEWORK: NORTH AMERICA PSYCHEDELIC DRUGS MARKET 50

• 5.1 REGULATORY SCENARIO IN THE U.S. 50
• 5.2 REGULATORY SCENARIO IN THE U.K. 51
• 5.3 REGULATORY SCENARIO IN INDIA 52
• 5.4 REGULATORY SCENARIO IN UAE 52
• 5.5 REGULATORY SCENARIO IN AFRICA 53
• 5.6 REGULATORY SCENARIO IN BRAZIL 53

6 MARKET OVERVIEW 55

• 6.1 DRIVERS 57
  • 6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION 57
  • 6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 59
  • 6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH 62
  • 6.1.4 ONGOING CLINICAL TRIALS 63
  • 6.1.5 RISE IN PRODUCT APPROVALS 64
• 6.2 RESTRAINTS 64
  • 6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 64
  • 6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 67
  • 6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 68
• 6.3 OPPORTUNITIES 69
  • 6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 69
  • 6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 71
  • 6.3.3 UPCOMING REHABILITATION CENTERS 72
  • 6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 73
• 6.4 CHALLENGES 73
  • 6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 73
  • 6.4.2 RISE IN ILLEGAL ALTERNATIVES 75
  • 6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 75

7 COVID-19 IMPACT ON THE NORTH AMERICA PSYCHEDELIC DRUGS MARKET 76

• 7.1 IMPACT ON PRICE 76
• 7.2 IMPACT ON DEMAND 76
• 7.3 IMPACT ON SUPPLY CHAIN 77
• 7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 77
• 7.5 CONCLUSION 78

8 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY TYPE 79

• 8.1 OVERVIEW 80
• 8.2 EMPATHOGENS 83
• 8.3 DISSOCIATIVES 84
• 8.4 OTHERS 85

9 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY SOURCE 86

• 9.1 OVERVIEW 87
• 9.2 SYNTHETIC 90
• 9.3 NATURAL 91

10 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUGS 92

• 10.1 OVERVIEW 93
• 10.2 GAMMA-HYDROXYBUTYRIC ACID 96
• 10.3 KETAMINE 97
• 10.4 PSILOCYBIN 98
• 10.5 OTHERS 99

11 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION 100

• 11.1 OVERVIEW 101
• 11.2 NARCOLEPSY 104
• 11.3 TREATMENT RESISTANT DEPRESSION 105
• 11.4 MAJOR DEPRESSIVE DISORDER 106
• 11.5 OPIATE ADDICTION 107
• 11.6 POST-TRAUMATIC STRESS DISORDER 108
• 11.7 OTHERS 109

12 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 110

• 12.1 OVERVIEW 111
• 12.2 ORAL 114
• 12.3 INHALATION 115
• 12.4 INJECTABLE 116

13 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER 117

• 13.1 OVERVIEW 118
• 13.2 HOSPITALS 121
• 13.3 SPECIALTY CLINICS 122
• 13.4 HOMECARE 123
• 13.5 OTHERS 124

14 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 125

• 14.1 OVERVIEW 126
• 14.2 HOSPITALS PHARMACY 129
• 14.3 RETAIL PHARMACY 130
• 14.4 ONLINE PHARMACY 131

15 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY REGION 132

• 15.1 NORTH AMERICA 133
  • 15.1.1 U.S. 140
  • 15.1.2 CANADA 142
  • 15.1.3 MEXICO 144

16 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 146

• 16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 146

17 SWOT ANALYSIS 147

18 COMPANY PROFILE 148

• 18.1 JAZZ PHARMACEUTICALS, INC. 148
  • 18.1.1 COMPANY SNAPSHOT 148
  • 18.1.2 REVENUE ANALYSIS 149
  • 18.1.3 COMPANY SHARE ANALYSIS 149
  • 18.1.4 PRODUCT PORTFOLIO 149
  • 18.1.5 RECENT DEVELOPMENTS 150
• 18.2 PFIZER INC. 151
  • 18.2.1 COMPANY SNAPSHOT 151
  • 18.2.2 REVENUE ANALYSIS 151
  • 18.2.3 COMPANY SHARE ANALYSIS 152
  • 18.2.4 PRODUCT PORTFOLIO 152
  • 18.2.5 RECENT DEVELOPMENTS 152
• 18.3 F. HOFFMANN- LA ROCHE LTD 153
  • 18.3.1 COMPANY SNAPSHOT 153
  • 18.3.2 REVENUE ANALYSIS 153
  • 18.3.3 COMPANY SHARE ANALYSIS 154
  • 18.3.4 PRODUCT PORTFOLIO 154
  • 18.3.5 RECENT DEVELOPMENT 154
• 18.4 JANSSEN NORTH AMERICA SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 155
  • 18.4.1 COMPANY SNAPSHOT 155
  • 18.4.2 COMPANY SHARE ANALYSIS 155
  • 18.4.3 PRODUCT PORTFOLIO 156
  • 18.4.4 RECENT DEVELOPMENT 156
• 18.5 AVADEL 157
  • 18.5.1 COMPANY SNAPSHOT 157
  • 18.5.2 PRODUCT PORTFOLIO 157
  • 18.5.3 RECENT DEVELOPMENT 157
• 18.6 CELON PHARMA SA 158
  • 18.6.1 COMPANY SNAPSHOT 158
  • 18.6.2 PRODUCT PORTFOLIO 158
  • 18.6.3 RECENT DEVELOPMENT 158

• 18.7 COMPASS 159
  • 18.7.1 COMPANY SNAPSHOT 159
  • 18.7.2 PRODUCT PORTFOLIO 159
  • 18.7.3 RECENT DEVELOPMENTS 159
• 18.8 CYBIN CORP. 160
  • 18.8.1 COMPANY SNAPSHOT 160
  • 18.8.2 PRODUCT PORTFOLIO 160
  • 18.8.3 RECENT DEVELOPMENTS 160
• 18.9 ENTHEON BIOMEDICAL CORP 161
  • 18.9.1 COMPANY SNAPSHOT 161
  • 18.9.2 PRODUCT PORTFOLIO 161
  • 18.9.3 RECENT DEVELOPMENT 161
• 18.10 GH RESEARCH 162
  • 18.10.1 COMPANY SNAPSHOT 162
  • 18.10.2 PRODUCT PORTFOLIO 162
  • 18.10.3 RECENT DEVELOPMENT 162
• 18.11 HIKMA PHARMACEUTICALS PLC 163
  • 18.11.1 COMPANY SNAPSHOT 163
  • 18.11.2 REVENUE ANALYSIS 163
  • 18.11.3 PRODUCT PORTFOLIO 164
  • 18.11.4 RECENT DEVELOPMENTS 164
• 18.12 NRX PHARMACEUTICALS, INC. 165
  • 18.12.1 COMPANY SNAPSHOT 165
  • 18.12.2 PRODUCT PORTFOLIO 165
  • 18.12.3 RECENT DEVELOPMENT 165
• 18.13 PHARMATHER HOLDINGS LTD. 166
  • 18.13.1 COMPANY SNAPSHOT 166
  • 18.13.2 PRODUCT PORTFOLIO 166
  • 18.13.3 RECENT DEVELOPMENT 166
• 18.14 VERRIAN 167
  • 18.14.1 COMPANY SNAPSHOT 167
  • 18.14.2 PRODUCT PORTFOLIO 167
  • 18.14.3 RECENT DEVELOPMENT 167
• 18.15 USONAINSTITUTE.ORG 168
  • 18.15.1 COMPANY SNAPSHOT 168
  • 18.15.2 PRODUCT PORTFOLIO 168
  • 18.15.3 RECENT DEVELOPMENT 168

19 QUESTIONNAIRE 169

20 RELATED REPORTS 173

LIST OF TABLES

• TABLE 1 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, PIPELINE ANALYSIS 37
• TABLE 2 PSYCHEDELICS RESEARCH STUDIES, IN EUROPE 49
• TABLE 3 MENTAL ILLNESS IN THE U.S. ADULTS, IN 2020 51
• TABLE 4 MENTAL DISORDERS, IN THE U.S. ADULTS, IN 2020 51
• TABLE 5 DRUG DEVELOPMENT PATHWAY FOR FDA APPROVAL OF NEW MEDICATIONS 56
• TABLE 6 THE 1971 UN CONVENTION ON PSYCHOTROPIC SUBSTANCES 58
• TABLE 7 MAGIC MUSHROOMS PRICES FOR RESEARCHERS, IN THE U.S. 59
• TABLE 8 COST OF PSYCHEDELIC DRUGS 59
• TABLE 9 PSYCHEDELIC DRUGS R&D ACTIVITIES 60
• TABLE 10 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 73
• TABLE 11 NORTH AMERICA EMPATHOGENS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 74
• TABLE 12 NORTH AMERICA DISSOCIATIVES IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 75
• TABLE 13 NORTH AMERICA OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 76
• TABLE 14 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION) 80
• TABLE 15 NORTH AMERICA SYNTHETIC IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 81
• TABLE 16 NORTH AMERICA NATURAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 82
• TABLE 17 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION) 86
• TABLE 18 NORTH AMERICA GAMMA-HYDROXYBUTYRIC ACID IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 87
• TABLE 19 NORTH AMERICA KETAMINE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 88
• TABLE 20 NORTH AMERICA PSILOCYBIN IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 89
• TABLE 21 NORTH AMERICA OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 90
• TABLE 22 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 94
• TABLE 23 NORTH AMERICA NARCOLEPSY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 95
• TABLE 24 NORTH AMERICA TREATMENT RESISTANT DEPRESSION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 96
• TABLE 25 NORTH AMERICA MAJOR DEPRESSIVE DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 97
• TABLE 26 NORTH AMERICA OPIATE ADDICTION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 98
• TABLE 27 NORTH AMERICA POST-TRAUMATIC STRESS DISORDER IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 99
• TABLE 28 NORTH AMERICA OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 100
• TABLE 29 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 104
• TABLE 30 NORTH AMERICA ORAL IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 105
• TABLE 31 NORTH AMERICA INHALATION IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 106
• TABLE 32 NORTH AMERICA INJECTABLE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 107
• TABLE 33 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 111
• TABLE 34 NORTH AMERICA HOSPITALS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 112
• TABLE 35 NORTH AMERICA SPECIALTY CLINICS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 113
• TABLE 36 NORTH AMERICA HOMECARE IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 114
• TABLE 37 NORTH AMERICA OTHERS IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 115
• TABLE 38 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 119
• TABLE 39 NORTH AMERICA HOSPITALS PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 120
• TABLE 40 NORTH AMERICA RETAIL PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 121
• TABLE 41 NORTH AMERICA ONLINE PHARMACY IN PSYCHEDELIC DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 122
• TABLE 42 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 129
• TABLE 43 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 129
• TABLE 44 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION) 129
• TABLE 45 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION) 129
• TABLE 46 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 130
• TABLE 47 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 130
• TABLE 48 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 130
• TABLE 49 NORTH AMERICA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 130
• TABLE 50 U.S. PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
• TABLE 51 U.S. PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION) 131
• TABLE 52 U.S. PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION) 131
• TABLE 53 U.S. PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 131
• TABLE 54 U.S. PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 132
• TABLE 55 U.S. PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 132
• TABLE 56 U.S. PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 132
• TABLE 57 CANADA PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 133
• TABLE 58 CANADA PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION) 133
• TABLE 59 CANADA PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION) 133
• TABLE 60 CANADA PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 133
• TABLE 61 CANADA PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 134
• TABLE 62 CANADA PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 134
• TABLE 63 CANADA PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 134
• TABLE 64 MEXICO PSYCHEDELIC DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
• TABLE 65 MEXICO PSYCHEDELIC DRUGS MARKET, BY SOURCE, 2020-2029 (USD MILLION) 135
• TABLE 66 MEXICO PSYCHEDELIC DRUGS MARKET, BY DRUGS, 2020-2029 (USD MILLION) 135
• TABLE 67 MEXICO PSYCHEDELIC DRUGS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 135
• TABLE 68 MEXICO PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 136
• TABLE 69 MEXICO PSYCHEDELIC DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 136
• TABLE 70 MEXICO PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 136

LIST OF FIGURES

• FIGURE 1 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: SEGMENTATION 20
• FIGURE 2 NORTH AMERICA PSYCHEDELIC DRUGS MARKET : DATA TRIANGULATION 23
• FIGURE 3 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: DROC ANALYSIS 24
• FIGURE 4 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 25
• FIGURE 5 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: COMPANY RESEARCH ANALYSIS 25
• FIGURE 6 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: MULTIVARIATE MODELLING 26
• FIGURE 7 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: INTERVIEW DEMOGRAPHICS 27
• FIGURE 8 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: DBMR MARKET POSITION GRID 28
• FIGURE 9 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: END USER COVERAGE GRID 29
• FIGURE 10 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: VENDOR SHARE ANALYSIS 30
• FIGURE 11 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: SEGMENTATION 34
• FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA PSYCHEDELIC DRUGS MARKET GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 35
• FIGURE 13 RISING AWARENESS TOWARDS MERANTAL HEALTH DRIVING THE NORTH AMERICA PSYCHEDELIC DRUGS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 36
• FIGURE 14 EMPATHOGENS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PSYCHEDELIC DRUGS MARKET IN 2022 & 2029 36
• FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PSYCHEDELIC DRUGS MARKET 47
• FIGURE 16 MENTAL ILLNESS AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS 51
• FIGURE 17 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY DEMOGRAPHIC GROUPS 52
• FIGURE 18 MENTAL ILLNESS TREATMENT RATES AMONG THE U.S. ADULTS, IN 2020, (IN %), BY GENDER 53
• FIGURE 19 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY TYPE, 2021 71
• FIGURE 20 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY TYPE, 2022-2029 (USD MILLION) 72
• FIGURE 21 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY TYPE, CAGR (2022-2029) 72
• FIGURE 22 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY TYPE, LIFELINE CURVE 73
• FIGURE 23 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2021 78
• FIGURE 24 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY SOURCE, 2022-2029 (USD MILLION) 79
• FIGURE 25 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY SOURCE, CAGR (2022-2029) 79
• FIGURE 26 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY SOURCE, LIFELINE CURVE 80
• FIGURE 27 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2021 84
• FIGURE 28 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DRUGS, 2022-2029 (USD MILLION) 85
• FIGURE 29 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DRUGS, CAGR (2022-2029) 85
• FIGURE 30 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DRUGS, LIFELINE CURVE 86
• FIGURE 31 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2021 92
• FIGURE 32 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY APPLICATION, 2022-2029 (USD MILLION) 93
• FIGURE 33 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY APPLICATION, CAGR (2022-2029) 93
• FIGURE 34 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY APPLICATION, LIFELINE CURVE 94
• FIGURE 35 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021 102
• FIGURE 36 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 103
• FIGURE 37 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 103
• FIGURE 38 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 104
• FIGURE 39 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY END USER, 2021 109
• FIGURE 40 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION) 110
• FIGURE 41 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY END USER, CAGR (2022-2029) 110
• FIGURE 42 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY END USER, LIFELINE CURVE 111
• FIGURE 43 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021 117
• FIGURE 44 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 118
• FIGURE 45 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 118
• FIGURE 46 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 119
• FIGURE 47 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: SNAPSHOT (2021) 125
• FIGURE 48 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021) 127
• FIGURE 49 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2022 & 2029) 127
• FIGURE 50 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY COUNTRY (2021 & 2029) 128
• FIGURE 51 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: BY TYPE (2022-2029) 128
• FIGURE 52 NORTH AMERICA PSYCHEDELIC DRUGS MARKET: COMPANY SHARE 2021 (%) 137